1. Introduction {#sec1}
===============

Immune thrombocytopenic purpura (ITP) is a frequent complication in patients with Autoimmune LymphoProliferative Syndrome (ALPS), occurring in up to 40% of patients \[[@B1], [@B2]\]. ALPS, caused by mutations in the *FAS* apoptotic pathway \[[@B1]\], can be diagnosed in young adults, often at the onset of autoimmune cytopenia, while chronic lymphoproliferation is less prominent than in childhood \[[@B3]\]. In a recent study, Vandrovcova et al. screened a cohort of 130 adult patients with persistent or chronic primary ITP for mutations in the *FAS* gene and identified two potentially functional mutations in two patients with atypical ALPS clinical features \[[@B4]\]. Otherwise, Evans syndrome, characterized by the combination of autoimmune hemolytic anemia and ITP, is potentially genetically determined in at least 65% of cases in pediatric population \[[@B5]\]. So, these observations raise the possibility of a genetic defect in ITP young people, mostly in a context of immunodeficiency, and ALPS mutations must primarily be investigated. Then, we report another original case of a young woman who developed an immunodeficiency leading to fatal pulmonary Epstein--Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL), 3 years after stopping Rituximab (RTX) prescribed for ITP. Genetic testing led us to identify an unknown heterozygous mutation in the FAS(CD95)-ligand gene *(FASLG)* and its role in this patient\'s immunodepression is discussed.

2. Clinical Case {#sec2}
================

In July 2015, a 24-year-old woman was referred to our Department of Internal Medicine for a high fever (39°C) lasting 3 days, fatigue, myalgias, chills, and vomiting. She had been followed since 2008 for primary ITP, initially treated with oral prednisone (1 mg/kg/day), which achieved complete remission. Because of occasional severe relapses (two between 2009 and 2012, with gynecological bleeding), she was subsequently treated with Intravenous Immunoglobulin (IVIg) with good responses. In January 2012, at age 21, she suffered a severe relapse, again justifying the use of IVIg and corticosteroids. At that time, she had detectable autoimmunity with an antinuclear antibody titer of 1 : 250 (anti-SSA specificity but without any sign suggestive of lupus) and platelet-directed anti-glycoprotein IIb/IIIa antibodies. In June 2012 (baseline), a new IVIg cycle was administered, followed by RTX (375 mg/m^2^ once-a-week for 4 consecutive weeks). A complete platelet response was obtained within 6 weeks and, at the last follow-up (March 2015), her blood platelet level was normal (321 × 10^9^/L) without treatment. Before RTX infusion (June 2012), her blood total gamma-globulin level \>3 months before IVIg infusion had been normal (8.9 g/L) but she was lymphopenic (total lymphocytes: 0.513 × 10^9^/L), while her peripheral blood lymphocyte count had been normal at ITP diagnosis (1.199 × 10^9^/L). The previously available phenotype profiles of her peripheral circulating lymphocytes are reported in [Table 1](#tab1){ref-type="table"}. No infection occurred during the 3 years following the last RTX administration and she remained clinically well at biannual consultations in our department.

At admission, in July 2015, at age 24, her temperature was 39.2°C and she complained of lower abdominal pain, vomiting but without diarrhea; her physical examination was normal. Laboratory tests showed elevated C-reactive protein (CRP: 114 mg/L, normal range (NR): \<5 mg/L), hepatic cytolysis (aspartate aminotransferase: 144 U/L, NR: 7--40 U/L; alanine aminotransferase: 265 U/L, NR: 5--50 U/L) and cholestasis (alkaline phosphatase: 389 IU/L, NR: 40--130 U/L; *γ*-glutamyltranspeptidase: 698 U/L, NR: 5--38 U/L). The hemogram revealed agranulocytosis and thrombocytopenia (leukocytes: 4.9 × 10^9^/L; neutrophils: 0.02 × 10^9^/L; hemoglobin: 14.5 g/dL; platelets: 46 × 10^9^/L). Bone-marrow aspirate showed normal density, several megakaryocytes but hypoplastic granulopoiesis in blocked maturation, without blasts. Computed-tomography (CT) scans of the thorax and abdomen were normal. Once urine and blood samples had been collected, empirical ceftazidime and gentamicin were begun, and achieved apyrexia within 48 h. After 46 h, blood cultures came back positive for *Campylobacter jejuni*, and the identical strain isolated from the patient\'s feces; amoxicillin--clavulanic acid (1 g 3 times a day for 2 weeks) was prescribed. Seven days postadmission, CRP, neutrophil and platelet levels returned to normal (3 mg/L, 6.61 × 10^9^/L and 521 × 10^9^/L, respectively); blood cultures were negative; and liver function was improved.

Laboratory evaluation for immunodeficiency yielded: negative serology for human immunodeficiency viruses-1 and -2, very low serum Ig levels ([Table 1](#tab1){ref-type="table"}) and no circulating B cells. Flow-cytometry quantification of T-cell subsets found expansion of circulating CD4^+^ T lymphocytes expressing surface DR, suggesting their activation; low natural killer cells and CD8^+^ T-lymphocyte levels. Urine immunofixation electrophoresis was negative. Ig-replacement therapy was started but not pursued by the patient.

Ten months later (May 2016, age 25) she was hospitalized for a 15-day low-grade fever, weight loss, nonproductive cough and progressive dyspnea. CRP, lactate dehydrogenase and *β*~2~-microglobulin levels were 40 mg/L, 340 U/L (NR 5--240 U/L) and 3.53 mg/L (NR 1.2--2.5 mg/L), respectively. As shown in [Table 1](#tab1){ref-type="table"}, hypogammaglobulinemia, CD19^+^ B lymphopenia and low peripheral CD8^+^ T-cell count persisted but without T activation, as assessed by HLADR-positivity. CT scans visualized bilateral diffuse infiltrates, ground-glass opacities and large nodules. Bronchoalveolar lavage analysis revealed *Pneumocystis jiroveci* cysts with positive polymerase chain reaction (PCR) (4,000 copies/mL); high-dose trimethoprim--sulfamethoxazole and corticosteroids were prescribed. Searches for other pathogens, including *Mycobacterium tuberculosis*, atypical mycobacteria, cytomegalovirus, *Cryptococcus* and *Aspergillus* species, were negative. At that time, her bone-marrow biopsy was normal.

Despite appropriate antibiotics and clinical improvement, thoracic CT scans revealed worsened dense infiltrates ([Figure 1(a)](#fig1){ref-type="fig"}), pleural effusions, hepatosplenomegaly and nodular lesions of both kidneys ([Figure 1(b)](#fig1){ref-type="fig"}). A new bronchoscopy with biopsies found CD20+ large lymphomatous cell infiltration ([Figure 2](#fig2){ref-type="fig"}) in bronchi. Those large atypical lymphoid tumor cells were CD10^−^BCL-6^−^ and MUM1^+^BCL-2^+^, with an 80% Ki-67--proliferation index on immunolabeling. EBV, as assessed by in situ hybridization with an EBV-encoded small RNA probe, was diffusely positive in about 80% of tumor cells ([Figure 2](#fig2){ref-type="fig"}). The FISH assay for *MYC* gene rearrangement (MYC FISH DNA Probe, Split Signal, (Y5410), Dako, Locus 8q24) was negative. EBV-positive DLBCL with a nongerminal center phenotype was diagnosed without bone-marrow infiltration. Circulating EBV-DNA was positive (2,430,000 IU/mL). DLBCL treatment consisted of RTX, cyclophosphamide, doxorubicin, vincristine and prednisone. Even with EB viremia becoming negative, she developed fever, cytopenias, liver damage and neurological manifestations, as a consequence of her prominent bone-marrow hemophagocytosis. Unfortunately, she died of multiorgan failure at age 25.

3. Genetic Analyses {#sec3}
===================

DNA extracted using standard methods \[[@B6]\] from the bone-marrow sample obtained when she had *Pneumocystis jiroveci* pneumonia was subjected to next-generation sequencing. Exons from genomic DNA underwent PCR amplification according to standard protocols \[[@B5]\]. The PCR amplificons were then sequenced in both directions and analyzed with ApE-A plasmid Editor v2.0.45.

Using 1--3 *µ*g of DNA according to the manufacturer\'s protocol (Ovation Ultralow, Nugen Technologies), we constructed Illumina-compatible, pre-capture, bar-coded, genomic DNA libraries. Equimolar concentrations of several such pre-capture libraries were pooled and used with biotinylated probes from the SureSelect panel (Agilent, Les Ulis, France) for the capture process, and, finally, sequenced on an Illumina HiSeq2500 (paired-end sequencing 130 × 130 bases, high-throughput mode). Using the Burrows--Wheeler alignment version 0.6.2.13, the read sequences were aligned to reference human genome hg19. For each sample, depth of coverage reached at least a mean 300x; it covered ≥97% of the panel regions at 15× and ≥90% of them at least at 30x.

To identify all high-throughput sequencing-generated single nucleotide polymorphisms and insertions/deletions, the Genome-Analysis Toolkit and an in-house program (Polyweb) were used to filter the variants. We excluded variants representing \>1% of the populations previously reported in public databases: e.g., the 1000-genomes project, *Exome Variant Server*, double-base single nucleotide polymorphisms and in-house--identified variants (4047 exomes). The exomes were mined for variations, i.e., substitutions and insertions/deletions in the coding regions, splice sites and essential splice sites in the flanking introns. Coding-region silent mutations were excluded from this analysis.

The search for variants known to be associated with primary immune deficiency (PID) failed to reveal rare recessive or heterozygous mutations (i.e., in cytotoxic T-lymphocyte antigen-4 (*CTLA4*), phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit-*δ* (*PIK3CD*), phosphatidylinositol-4,5-bisphosphate 3-kinase, receptor-1 (*PIK3R1*), X-linked inhibitor of apoptosis (*XIAP*) and *FAS*). Our analysis focused on rare private variants with generally deleterious predictive scores: SIFT and PolyPhen2, the two most commonly used algorithms to predict negative impact on protein structure, and the Combined Annotation-Dependent Depletion (CADD) score \>20. Together they identified 69 unique private variants, four of which were missense mutations known to affect immune-deficiency--associated genes ([Table 2](#tab2){ref-type="table"}).

The FAS-ligand (*FASL*) gene (p.G167R), the first missense gene to be identified, was not in the Genome Aggregation Database (gnomAD) or ClinVar database. It is predicted to interfere with *FASL* extracellular domains. The *PRF1* (p.R55C) gene, which codes for perforin-1, was the second missense mutation. Among its 58 entries in the gnomAD, one was homozygous. Familial hemophagocytotic lymphohistiocytosis is associated with homozygous *PRF1* mutations. Heterozygous (58 times) and homozygous (9 times) variants of the Bloom syndrome RecQ-Like helicase (*BLM*) gene, the third missense mutation, were found in the gnomAD. Its homozygous mutations are linked to the Bloom syndrome. In light of the frequency of the last two mutations in the public gnomAD, especially homozygous mutants, we considered them to be polymorphic variants. The fourth missense variant affects the membrane-organizing extension spike protein, which encodes Moesin (*MSN*) (p.A122T); it has already been listed three times in the gnomAD. *MSN* is located on the X chromosome. Although no one carrying homozygous *MSN* has yet been reported, hemizygous *MSN* mutations have been reported in patients with X-linked PID \[[@B7]\]. The deleterious prediction algorithms used for this variant yielded totally discordant findings: SIFT indicated it is innocuous, PolyPhen2 suggested it is probably.

4. Discussion {#sec4}
=============

This case is uncommon because of the prolonged hypogammaglobulinemia persisting after RTX discontinuation and then, secondarily, after *Campylobacter* infection, the appearance of uncontrolled EBV-induced lymphoproliferation. Several papers alerted clinicians to the risk of symptomatic hypogammaglobulinemia \>2 years after RTX administration to ITP patients with initially normal Ig levels (reviewed in \[[@B8]\]). So, did our patient have transient RTX-induced hypogammaglobulinemia or RTX-unmasked underlying humoral PID? The latter hypothesis seems the most likely. Indeed, B-cell lymphopenia is certainly observed for several months after RTX administration but usually not for \>3 years \[[@B9]\]. Shortly before the first RTX infusion, our patient was already B-cell lymphopenic. It would have been highly informative to have a detailed naïve/memory B-cell phenotype, notably the percentage of switched-memory B cells, as it is usually low in Common Variable Immunodeficiency (CVID) with autoimmune manifestations. Many primary humoral defects, e.g. CVID, can be preceded and/or revealed by autoimmune manifestations like ITP, as for our patient. Lastly, the authors reporting extremely severe hypogammaglobulinemia 7 years after treatment of indolent lymphoma \[[@B10]\] postulated worsening of preexisting CVID.

The discovery of our patient\'s *FASL* gene mutation could suggest atypical ALPS. Indeed, ALPS has been associated with recessive and dominant *FASL* gene mutations \[[@B11]--[@B14]\]. It is predicted to interfere with *FASL* extracellular domains. However, the causality of those heterozygous *FASL* gene mutations was not definitively confirmed \[[@B15]\]. The variant c.499G\>A present in our patient has never been described in general population nor in the context of autoimmune disease, and may be a "probably pathogenic" mutation. Some ALPS *FAS*-mutated patients experience their first symptoms, particularly autoimmune cytopenia, in adulthood \[[@B3]\]. Unfortunately, plasma biomarkers, now routinely assayed during the prediagnosis work-up for ALPS-FAS, such as soluble FASL (sFASL) or interleukins 10 and 18 \[[@B16]\], can no longer be determined for our deceased patient. It is therefore difficult to consider an ALPS diagnosis for our patient because she had neither splenomegaly nor lymphadenopathy, and no accumulation of a peripheral population of TCR*αβ*^+^CD4^−^CD8^−^ T cells (referred to as double-negative (DN) T cells) ([Table 1](#tab1){ref-type="table"}), the pathognomonic feature of ALPS, was observed. Moreover, her blood vitamin-B~12~ level was normal. However, the two ITP patients described by Vandrovcova et al. with nonsynonymous heterozygous variants in FAS had few classical features of ALPS \[[@B4]\]. For example, the patient with the p.Cys199Arg mutation (located outside the death domain and resulting in aberrant signaling), had no hepatosplenomegaly nor lymphadenopathy and slightly increased *αβ*-DN T cells \[[@B4]\]. These observations raise possible relation between unusual ALPS phenotypes and novel types of mutations in both FAS and the death ligand *FasL*. Although putative contributions of the *FASL* and *PRF1* genes mutations could be advanced for our patient, we have no possible logical pathophysiological mechanisms to explain her fatal disease.

A potential role of the *MSN* mutation could have been contributory, given the immune deficiency observed in hemizygous patients \[[@B7]\]. Heterozygous females with X-linked gene mutations have developed attenuated or even severe clinical \[[@B17], [@B18]\], inhibitor of nuclear factor (NF) *κ*B kinase subunit-*γ*/NF-*κ*B essential modulator (*IKBKG/NEMO*) gene mutations, with incontinentia pigmenti being the most well-known example. While deleterious mutations are usually lethal in males, the Moesin-associated disease develops variably in heterozygous females. Moreover, *IKBKG* hypomorphic hemizygous mutations are associated with ectodermal dysplasia, anhidrotic lymphedema and immunodeficiency. More recently, *XIAP* mutations, associated with an EBV-triggered lymphoproliferative syndrome in hemizygous males \[[@B19]\], have been found in heterozygous females with erythroderma nodosa and/or inflammatory bowel disease resulting from random X-inactivation \[[@B20]\]. Although such epigenetic events have never been reported in the few known cases of *MSN*-mutation--associated immunodeficiency, that hypothesis cannot be excluded at present. Further analyses of blood samples would have been needed to support/refute it.

In conclusion, our observation strengthens the involvement of *FASL* gene mutation as causative agent of severe clinical phenotypes of PID, and raises new questions about the genetic background of ITP occurring in young people in a context of immunodeficiency. Wide-ranging genetic screening should be then proposed to these patients, focusing on mutations known to be strong risk factors for autoimmune cytopenia such as FAS and FASL mutations. All patients with autoimmune cytopenia should have their blood Ig levels determined, because ITP can be the first manifestation of PID, and monitored after a disease-modifying treatment, like RTX or splenectomy, is undertaken. Henceforth, early PID diagnosis in young patients is challenging for critically ill patients to choose the best adapted regimen, including targeted-immunotherapy or even hemopoietic stem-cell transplantation.
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![Imaging. (a) Pulmonary computed-tomography (CT) scan showing diffuse bilateral infiltrates. (b) CT with intravenous contrast showing enlargement of both kidneys with bilateral renal nodules.](CRII2019-2543038.001){#fig1}

![Histology. (a) Lymphomatous infiltration in the bronchial mucosa (hematoxylin--eosin (HE) staining, ×40). (b) Large diffuse large B-cell lymphoma (DLBCL) cells characterized by nuclei with prominent nucleoli on a background of tumoral necrosis (HE, ×400). (c) CD20+ labeling of the DLBCL cells. (d) Epstein--Barr virus-encoded RNA-1 expressed by DLBCL cells.](CRII2019-2543038.002){#fig2}

###### 

Summary of the patient\'s immunological profile.

  Parameter                            Normal range   At ITP diagnosis (2008)   6 months before RTX   Baseline^∗^   6 months post-RTX   Jul 2015   Nov 2015   May 2016
  ------------------------------------ -------------- ------------------------- --------------------- ------------- ------------------- ---------- ---------- ----------
  Blood hemoglobin, g/dL               12--16         14.8                      12.1                  13.7          14.3                14.5       13.6       11.9
  Blood platelets, G/L                 150--400       3                         2                     24            368                 49         322        404
  Blood leukocytes, /mm^3^             4000--10,000   6,300                     3,750                 5,800         4,890               4,100      5,200      6,600
  Blood neutrophils, /mm^3^            2,500--7,500   4,570                     2,670                 4,950         3,590               120        3,100      5,430
  Monocytes, /mm^3^                    200--1,000     370                                             190           270                 600        370        400
  Total blood gamma-globulins, g/L     7.8--16        8.4                                             8.9           ND                  2.3        2.6        2.8
   IgG                                 6.90--14       ND                        ND                    ND            ND                  2.19       2.37       2.86
   IgA                                 0.70--3.70     ND                        ND                    ND            ND                  0.477      0.52       0.51
   IgM                                 0.40--2.40     ND                        ND                    ND            ND                  0.11       0          0.2
  Total lymphocytes/mm^3^                             1,199                     513                   589           705                 3,000      861        402
   CD19^+^ B cells, %                  11--16         18.13                     ND                    16.75         0                   0          0          0
   CD19^+^ B cells/mm^3^               200--400       217                       ND                    99            0                   0          0          0
   CD3^+^ T cells/mm^3^                1,100--1,700   923                       422                   453           607                 2,949      757        317
   CD4^+^T cells/mm^3^                 700--1,100     745                       330                   359           456                 2,774      589        252
   CD8^+^ T cells/mm^3^                500--900       138                       69                    74            131                 132        151        54
   CD4^+^/CD8^+^ ratio                                5.39                      4.78                  4.85          3.5                 21         12         4.6
   CD3^+^CD4^--^CD8^--^T cells/mm^3^                  37                        21                    18            17                  43         40         7
   *γδ* T Lymphocytes/mm^3^                           ND                        ND                    ND            6                   ND         ND         3
   CD4^+^DR^+^ T cells, %                             4.03                      7.88                  4.5           3.7                 59.1       ND         9.59
   CD8^+^DR^+^ T cells, %                             16.67                     29                    17.8          5.5                 19.7       ND         12.96
   CD3^--^CD16^+^CD56^+^ NK/mm^3^      200--400       ND                        ND                    18            7                   27         ND         20

^∗^Baseline, 2012 just prior to first rituximab infusion. ND: not determined. NR: normal range, NK: natural killers.

###### 

Sequencing results of heterozygous PID-related variants affecting the *FASL*, *PRF1*, *BLM*, and *MSN* genes.

  Gene     Consequence   Transcript           Exon   cDNA_Pos   Cds_Pos   AA    Protein_Pos   Nomenclature   PolyPhen                           SIFT                        CADD
  -------- ------------- -------------------- ------ ---------- --------- ----- ------------- -------------- ---------------------------------- --------------------------- ------
  *FASL*   Missense      ENST00000367721_1    4      683        499       G/R   167           c.499G\>A      Probably damaging (score: 1)       Deleterious (score: 0)      27.5
  *PRF1*   Missense      ENST00000441259_10   2      324        163       R/C   55            c.163C\>T      Probably damaging (score: 0.959)   Deleterious (score: 0)      26.6
  *BLM*    Missense      ENST00000355112_15   2      161        43        R/C   15            c.43C\>T       Probably damaging (score: 0.939)   Deleterious (score: 0.02)   34
  *MSN*    Missense      ENST00000360270_X    4      536        364       A/T   122           c.364G\>A      Possibly damaging (score: 0.718)   Benign (score: 0.09)        25.6
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